Back
Dentsply Sirona 10K Form
Sell
32
XRAY
Dentsply Sirona
Last Price:
31.07
Seasonality Move:
2.55%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-02-29 | 10K | XRAY/Dentsply Sirona Annual |
| 2023-11-02 | 10Q | XRAY/Dentsply Sirona Quarterly |
| 2023-08-07 | 10K | XRAY/Dentsply Sirona Annual |
| 2023-05-03 | 10Q | XRAY/Dentsply Sirona Quarterly |
| 2023-03-01 | 10K | XRAY/Dentsply Sirona Annual |
| 2022-11-14 | 10Q | XRAY/Dentsply Sirona Quarterly |
Receive XRAY News And Ratings
See the #1 stock for the next 7 days that we like better than XRAY
XRAY Financial Statistics
Sales & Book Value
| Annual Sales: | $3.97B |
|---|---|
| Cash Flow: | $120M |
| Price / Cash Flow: | 29.15 |
| Annual Sales: | $15.89 |
| Price / Book: | 1.97 |
Profitability
| EPS (TTM): | -0.62000 |
|---|---|
| Net Income (TTM): | $-132M |
| Gross Margin: | $2.09B |
| Return on Equity: | -3.7% |
| Return on Assets: | -1.76% |
Dentsply Sirona Earnings Forecast
Key Dentsply Sirona Financial Ratios
- The Gross Profit Margin over the past 38 years for XRAY is 52.61%.
- The Selling, General & Administrative Expenses for XRAY have been equal to 40.86% of Gross Profit Margin.
- The Research & Development expenses have been 4.64% of Revenue.
- The Interest Expense is -61.36% of Operating Income.
- The Net Earning history of XRAY is -3.33% of Total Revenues.
- Per Share Earnings over the last 38 years have been positive in 24 years.
Dentsply Sirona Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Current Symbol: | XRAY |
| CUSIP: | 24906P |
| Website: | dentsplysirona.com |
Debt
| Debt-to-Equity Ratio: | 0.64 |
|---|---|
| Current Ratio: | 1.38 |
| Quick Ratio: | 0.76 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 12.98 |
XRAY Technical Analysis vs Fundamental Analysis
Sell
32
Dentsply Sirona (XRAY)
is a Sell
Is Dentsply Sirona a Buy or a Sell?
-
Dentsply Sirona stock is rated a Sell
The current Dentsply Sirona [XRAY] share price is $30.89. The Score for XRAY is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.